Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 6/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypoxanthine SCHEMBL30266940 | 0.80 | TSHR (0.45) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| Hypoxanthine SCHEMBL29467372 | 0.69 | CYP1A2 (0.41) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| Guanine SCHEMBL29409531 | 0.69 | KDM4E (0.57) | LMNAXDHALDH1A1DYRK1APNP | |
| Hypoxanthine SCHEMBL30324467 | 0.69 | CYP1A2 (0.41) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| SCHEMBL14094281 | 0.67 | SMN1; SMN2 (0.46) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| SCHEMBL440223 | 0.65 | SMN1; SMN2 (0.40) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| SCHEMBL21440777 | 0.65 | ALDH1A1 (0.54) | RAB9AALDH1A1PDPK1ACHEGDA | |
| SCHEMBL10518128 | 0.64 | ALDH1A1 (0.53) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| SCHEMBL1992700 | 0.64 | PARP1 (0.41) | TSHRLMNAADORA2ASLC6A4ADRA1A | |
| Adenine SCHEMBL30176484 | 0.64 | ADORA2A (0.38) | LMNAADORA2AXDHRETLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318403-B2 | 2′3′-cyclic dinucleotides and prodrugs thereof | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2025-06-03 | — | — | US | disclosed |
| US-20240327339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | TSHR 4828/4885LMNA 2956/4885ADORA2A 121/4885 |
| US-12318403-B2 | 2′3′-cyclic dinucleotides and prodrugs thereof | STING1, CGAS, NT5C2 | TSHR 4821/4885LMNA 2874/4885ADORA2A 120/4885 |
| US-20240327339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ACE, ACE2, SARNP | TSHR 2881/4885LMNA 372/4885ADORA2A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.